Trial · NCT00040937

S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

NCT00040937, Phase 2, Completed, SWOG Cancer Research Network; results first posted 2013-07-17

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma. Trials, record NCT00040937. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00040937

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT number: NCT00040937
Status: Completed
Phases: Phase 2
Enrollment: 147 participants, actual
Lead sponsor: SWOG Cancer Research Network
Conditions: Multiple Myeloma
Interventions: filgrastim, sargramostim, cyclophosphamide, dexamethasone, melphalan, prednisone, thalidomide, peripheral blood stem cell transplantation
First posted: 2003-01-27
Last updated: 2016-12-08
Results first posted: 2013-07-17

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Overall Survival	4-7 years
Secondary	Assess Toxicity of Thalidomide/Dexamethasone as a Pre-transplant Induction Regimen.	Induction	To assess Grade 3-5 AE related to thalidomide/dexamethasone when administered as a pre-transplant induction regimen.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
SECONDARY	Assess Toxicity of Thalidomide/Dexamethasone as a Pre-transplant Induction Regimen.	Induction	All participants receiving at least one dose of induction therapy	Participants	NUMBER
PRIMARY	Overall Survival	4-7 years		proportion surviving at 4 years	NUMBER

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Assess Toxicity of Thalidomide/Dexamethasone as a Pre-transplant Induction Regimen.	Induction/PBSC Mobilization		2		Participants
Overall Survival	Treatment Arm		.64	95% Confidence Interval .55 to .74	proportion surviving at 4 years

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Induction/PBSC Mobilization	STARTED	Treatment Arm	147
Induction/PBSC Mobilization	COMPLETED	Treatment Arm	110
Induction/PBSC Mobilization	NOT COMPLETED	Treatment Arm	37
Autologous PBSCT	STARTED	Treatment Arm	108
Autologous PBSCT	COMPLETED	Treatment Arm	77
Autologous PBSCT	NOT COMPLETED	Treatment Arm	31
Maintenance	STARTED	Treatment Arm	76
Maintenance	COMPLETED	Treatment Arm	76
Maintenance	NOT COMPLETED	Treatment Arm	0

Source ClinicalTrials.gov

Adverse events333

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Anemia	Blood and lymphatic system disorders	Induction/PBSC Mobilization	73	140
other	Anemia	Blood and lymphatic system disorders	Autologous PBSCT	94	105
other	Anemia	Blood and lymphatic system disorders	Prednisone + Thalidomide	23	76
other	Febrile neutropenia	Blood and lymphatic system disorders	Induction/PBSC Mobilization	0	140
other	Febrile neutropenia	Blood and lymphatic system disorders	Autologous PBSCT	64	105
other	Febrile neutropenia	Blood and lymphatic system disorders	Prednisone + Thalidomide	0	76
other	Transplant-pRBC transfusion	Blood and lymphatic system disorders	Induction/PBSC Mobilization	0	140
other	Transplant-pRBC transfusion	Blood and lymphatic system disorders	Autologous PBSCT	7	105
other	Transplant-pRBC transfusion	Blood and lymphatic system disorders	Prednisone + Thalidomide	0	76
other	Transplant-plt transfusion	Blood and lymphatic system disorders	Induction/PBSC Mobilization	0	140

1 to 10 of 333Source ClinicalTrials.gov

See all 333 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Induction/PBSC Mobilization
Total, all-cause mortality	Autologous PBSCT
Total, all-cause mortality	Prednisone + Thalidomide
Total, other adverse events	Induction/PBSC Mobilization	140	140
Total, other adverse events	Autologous PBSCT	105	105
Total, other adverse events	Prednisone + Thalidomide	74	76
Total, serious adverse events	Induction/PBSC Mobilization	7	140
Total, serious adverse events	Autologous PBSCT	0	105
Total, serious adverse events	Prednisone + Thalidomide	1	76

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
19546405	RESULT

Source PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
U10CA032102	Southwest Oncology Group Treatment Grant	BLANKE, CHARLES D.	OREGON HEALTH & SCIENCE UNIVERSITY	NATIONAL CANCER INSTITUTE	1985 to 2013

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00040937

GET https://conductscience.org/api/trials/v1/NCT00040937/events?page=2

API reference For AI assistants